

## New method in synthesizing an optical active intermediate for (*R,R*)-formoterol

Wei Fan, Lei Chen, Li Hai, Yong Wu\*

Key Laboratory of Drug Targeting Education Ministry, West China School of Pharmacy,  
Sichuan University, Chengdu 610041, China

Received 23 October 2007

### Abstract

(*R*)-1-(4-Methoxyphenyl)propan-2-amine **2a**, an optical active intermediate for (*R,R*)-formoterol, was synthesized from D-alanine in 65% overall yield by using a simple route, which contained protecting amino group, cyclization, coupling with Grignard reagent, reduction and deprotection.

© 2008 Yong Wu. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

**Keywords:** (*R*)-1-(4-Methoxyphenyl)propan-2-amine; Formoterol; Intermediate; Synthesis

Fomoterol **1** (Fig. 1) is a new long-lasting  $\beta_2$ -adrenoceptor agonist which offers high selectivity for  $\beta_2$ -adrenoceptor, fast onset action and excellent safety [1]. Fomoterol is commercialized in the racemic form (*R,R* and *S,S*). But the *R,R* isomer **1a** is 5 times of intrinsic activity and 18 times of  $\beta_2$ -selectivity compared to *S,S* isomer **1b** [2]. Growing interest has been put into synthesizing (*R,R*)-formoterol [3] and one of the key procedures in this task is to prepare (*R*)-1-(4-methoxyphenyl)propan-2-amine **2a**.



Nichols et al. [4] reported the preparation of **2a** starting from 1-(4-methoxyphenyl)ethanone. However, this approach was not economical because of the expensive optically active amine reagent and low yield in fractional recrystallization. Kohno et al. [5] synthesized **2a** from expensive L-tyrosine, which was also too complicated. Recently, González-Sabín [6] reported a new method for preparing **2a** via enantioselective acetylation of racemic **2** catalyzed by *Candida antarctica* lipase B. This method also had a number of disadvantages that include applying costly enzyme catalyst and low overall yield. We herein reported a new synthetic approach of **2a** as outlined in Scheme 1.

D-Alanine was protected by CbzCl as the known method [7] to afford **4**, cyclizing with polyformaldehyde in the presence of TsOH in refluxed toluene to get **5**. **7** was obtained from **5** via coupling with Grignard reagent **6** in THF and treating by HCl [8]. Reduction of **7** by  $\text{Et}_3\text{SiH}$  in TFA [9] and Pd/C with  $\text{H}_2$  in alcohol respectively gave the final product **2a** [10,11].

In summary, we have provided a concise route starting from inexpensive D-alanine to prepare an optically active intermediate **2a** in synthesizing (*R,R*)-formoterol in five steps with 65% overall yield.

\* Corresponding author.

E-mail address: [smile.hl@163.com](mailto:smile.hl@163.com) (Y. Wu).

Fig. 1. The structure of compounds **1** and **2**.Scheme 1. The synthetic route of (*R*)-1-(4-methoxyphenyl)propan-2-amine.

## Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 29972013).

## References

- [1] D. Fudds, L.M. Hollingshend, K.L. Goa, et al. *Drugs* 42 (1991) 115.
- [2] D.A. Handley, C.H. Snanayake, W. Dutczak, et al. *Pulm. Pharmacol. Ther.* 15 (2002) 135.
- [3] F. Campos, M.P. Bosch, A. Guerrero, *Tetrahedron: Asymmetry* 11 (2000) 2705.
- [4] D.E. Nichols, C.F. Charles, D.B. Rusterholz, *J. Med. Chem.* 5 (1973) 480.
- [5] Kohno, T. Iwakuma, K. Yamada, *Syn. Commun.* 11 (1998) 1935.
- [6] J. González-Sabín, V. Gotor, F. Rebolledo, *Tetrahedron: Asymmetry* 13 (2002) 1315.H.
- [7] M.Y.H. Lai, M.A. Brimble, D.J. Calis, et al. *Bioorg. Med. Chem.* 12 (2005) 533.
- [8] Procedure for compound **7**: To solution of compound **5** (1.96 g, 8.33 mmol) in dry THF (20 mL) was added Grignard reagent **6** (10 mmol) in dry THF (10 mL) dropwisely at 0 °C in about 1 h, kept the temperature and stirred for another 2 h. 6 mol/L HCl (20 mL) was slowly added and stirred at room temperature for 12 h, then extracted with EtOAc 30 mL, washed with brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under vacuum to get compound **7** (2.24 g, 7.16 mmol) as a yellow oil, yield 86%.
- [9] Procedure for compound **8**: Et<sub>3</sub>SiH (1.16 g, 10 mmol) was added dropwise to a stirred solution of compound **7** (1.57 g, 5 mmol) in TFA (10 mL) at 0 °C in 0.25 h, followed by warming to room temperature for 10 h. The reaction mixture was poured into H<sub>2</sub>O (20 mL) and extracted with EtOAc (30 mL), the organic extracts was washed with saturated aqueous NaHCO<sub>3</sub>, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. The resulting yellow oil was purified by column chromatography to get compound **8** (1.17 g, 3.9 mmol) as a colorless solid, mp 88–90 °C, yield 78%.
- [10] Procedure for compound **2a**: A solution of compound **8** (1.0 g, 3.3 mmol) in alcohol (15 mL) was hydrogenated on 5% Pd/C (0.2 g) at atmospheric pressure and room temperature for 12 h. After removal of the catalyst, the filtrate was concentrated to get compound **2a** (0.53 g, 3.2 mmol) as a colorless oil, yield 97%.
- [11] Selected data for compound **2a**: IR (KBr): 3360, 3283, 2958, 1612, 1582, 1514, 1245, 805 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ ppm): 7.09 (d, 2H, *J* = 8.4 Hz), 6.83 (d, 2H, *J* = 8.4 Hz), 3.78 (s, 3H), 3.12 (m, 1H), 2.65 (dd, 1H, *J* = 5.2, 13.4 Hz), 2.48 (dd, 1H, *J* = 8.0, 13.2 Hz), 2.03 (b, 2H), 1.11 (d, 3H, *J* = 6.4 Hz); MS (*m/z*): 166 (*[M + H]*<sup>+</sup>); [ $\alpha$ ]<sub>D</sub><sup>20</sup> 35.6 (c 1.02, CHCl<sub>3</sub>); hydrochloride of **2a**: [ $\alpha$ ]<sub>D</sub><sup>20</sup> 22.7 (c 2.05, H<sub>2</sub>O), lit. [**3**]: [ $\alpha$ ]<sub>D</sub><sup>20</sup> 22.5 (c 2.00, H<sub>2</sub>O).